Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Immunology (Baltimore, Md. : 1950)|December 21, 2005
Hydrolytic and nonenzymatic functions of acetylcholinesterase comodulate hemopoietic stress responsesDan Grisaru, Marjorie Pick, Chava Perry, et al.
Plos One|December 17, 2011
Activation of the alternative NFκB pathway improves disease symptoms in a model of Sjogren's syndromeAdi Gilboa-Geffen, Yochai Wolf, Geula Hanin, et al.
Stem Cells (Dayton, Ohio)|November 29, 2008
Enforced expression of Mixl1 during mouse ES cell differentiation suppresses hematopoietic mesoderm and promotes endoderm formationSue Mei Lim, Lloyd Pereira, Michael S Wong, et al.
Haematologica|October 6, 2022
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trialNathalie Asherie, Shlomit Kfir-Erenfeld, Batia Avni, et al.
British Journal of Haematology|May 8, 2013
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activityMoshe E Gatt, Kohichi Takada, Mala Mani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2022
Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL AmyloidosisShlomit Kfir-Erenfeld, Nathalie Asherie, Sigal Grisariu, et al.
International Journal of Molecular Sciences|April 14, 2026
Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell TherapyIdo Cohen, Eyal Lebel, Sigal Grisariu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL AmyloidosisEyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.
Blood Advances|May 20, 2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myelomaShlomit Kfir-Erenfeld, Nathalie Asherie, Eyal Lebel, et al.
Pageof 3